Published in
American Society for Microbiology, Microbiology Spectrum, 3(10), 2022
DOI: 10.1128/spectrum.02292-21
Links
Tools
Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH Study)
Journal article published in 2022 by
Alba Bergas,
Adaia Albasanz-Puig 
,
Ana Fernández-Cruz,
Marina Machado,
Andrés Novo,
David van Duin ,
Carolina Garcia-Vidal,
Morgan Hakki,
Isabel Ruiz-Camps,
José Luis del Pozo,
Chiara Oltolini,
Catherine DeVoe,
Lubos Drgona,
Oriol Gasch,
Malgorzata Mikulska
and other authors.
,
Ana Fernández-Cruz,
Marina Machado,
Andrés Novo,
David van Duin ,
Carolina Garcia-Vidal,
Morgan Hakki,
Isabel Ruiz-Camps,
José Luis del Pozo,
Chiara Oltolini,
Catherine DeVoe,
Lubos Drgona,
Oriol Gasch,
Malgorzata Mikulska
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Data provided by 
Abstract
Ceftolozane-tazobactam (C/T) has been shown to be a safe and effective alternative for the treatment of difficult to treat infections due to Pseudomonas aeruginosa (PA) in the general nonimmunocompromised population. However, the experience of this agent in immunosuppressed neutropenic patients is very limited.